Ambrisentan - Noorik Biopharmaceuticals

Drug Profile

Ambrisentan - Noorik Biopharmaceuticals

Alternative Names: N-003

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Noorik Biopharmaceuticals
  • Class Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatorenal syndrome

Highest Development Phases

  • Phase II Hepatorenal syndrome
  • Preclinical Delayed graft function

Most Recent Events

  • 22 Nov 2016 Preclinical trials in Delayed graft function (Prevention) in Greece (unspecified route) before November 2016 (Noorik Biopharmaceuticals website, November 2016)
  • 22 Nov 2016 Ambrisentan is available for licensing as of 22 Nov 2016. http://www.noorik.com/
  • 04 Nov 2016 Phase-II clinical trials in Hepatorenal syndrome in Greece (IV) (EudraCT2016-002226-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top